Ignite Creation Date:
2024-05-06 @ 8:25 AM
Last Modification Date:
2024-10-26 @ 12:00 PM
Study NCT ID:
NCT02732639
Status:
COMPLETED
Last Update Posted:
2016-08-26
First Post:
2016-04-05
Brief Title:
A Study of Pegylated Interferon PEG-IFN Alfa-2a Pegasys in Participants With Chronic Hepatitis D CHD
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
Open-label Multicenter Trial Evaluating Efficacy and Safety of Peginterferon Alfa-2a PEGASYS in Patients With Chronic Hepatitis D CHD
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluated the efficacy and safety of 48-week treatment with pegylated interferon PEG-IFN alfa-2a Pegasys monotherapy in participants with chronic hepatitis D CHD Treatment was followed by 24 weeks of treatment-free follow-up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None